With the help of Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and The Aurora Funds, stem cell technology company Aldagen has closed an $18.4 million fourth round of funding. The company plans to use the funding to to advance four clinical-stage product candidates and for general corporate purposes. Durham, NC-based Aldagen has been developing adult stem cell therapies for leukemia, damaged heart muscles and other ailments.
- check out Aldagen's release
- read this report for more
ALSO: Malvern, PA-based CRO Frontage Laboratories has raised $10 million in growth equity funding. Release